Isarna Therapeutics Gmbh

Eugen Leo

Michel Janicot

Eugen Uhlmann

Frank Jaschinski

Katja Wosikowski-Buters

Petra Fettes

The present invention is directed to an oligonucleotide comprising a nucleic acid sequence of SEQ ID No. 1 or parts thereof, wherein 1 to 4 nucleotides at the 3'-end and/or at the 5&#x2032;-end of the oligonucleotide are modified at a base, a sugar and/or a phosphate for use in a method of reducing or inhibiting of scarring, of fibrotic closure of the trabeculectomy canal, of epithelial-to-mesenchymal transition of the trabecular meshwork and/or providing of protecting activity of the optic nerve optionally the optic nerve head. Further, the present invention refers to a pharmaceutical composition comprising such oligonucleotide and a pharmaceutically acceptable carrier.

TGF-beta oligonucleotide for use in treatment of ophthalmic diseases

The invention refers to an oligonucleotide consisting of 10 to 20 nucleotides of selected regions of the TGF-beta1, TGF-beta2 or TGF-beta3 nucleic acid sequence, which comprises modified nucleotides such as LNA, ENA, polyalkylene oxide-, 2'-fluoro, 2&#x2032;-O-methoxy and/or 2&#x2032;-O-methyl modified nucleotides. The invention further relates to pharmaceutical compositions comprising such oligonucleotide, wherein the composition or the oligonucleotide is used in a method for the prevention and/or treatment of glaucoma, posterior capsular opacification, dry eye, Marfan or Loeys-Dietz syndrome, riboblastoma, choroidcarcinoma, macular degeneration, such as age-related macular degeneration, diabetic macular endma, or cataract.

Growing community of inventors

Freiburg, Germany

Eugen Leo